Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Sanofi appoints Stefan Oelrich to its executive team

He joins as executive vice president, diabetes and cardiovascular

Lilly strengthens team with in-house promotions

And two senior leaders retire

- PMLiVE

Building a bright future

Mylan takes a bold approach as it doubles its pipeline through R&D and acquisitions

- PMLiVE

A New Managing Director Appointed for Lighthouse Medical Communications US

Lucid Group boost their US operations with the appointment of Andy Willmer as Managing Director for Lighthouse Medical Communications

Lucid Group Communications Limited

- PMLiVE

Ferring appoints executive VP and chief medical officer

Professor Klaus Dugi joins the pharma group from Boehringer Ingelheim

- PMLiVE

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Drug is also in phase II trial to treat PTSD patients

- PMLiVE

BMS appoints Saurabh Saha as senior VP, global head of translational medicine

He joins the R&D team from Atlas Venture

- PMLiVE

J&J files would-be prostate cancer blockbuster in US

Androgen receptor inhibitor achieves ‘significant’ MFS improvement over placebo

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

- PMLiVE

FDA fast-tracks Astellas’ Rydapt rival

AML treatment gilteritinib is currently involved in four phase III trials

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

Eli Lilly HQ

Prospects for Lilly’s Verzenio hit by botched lung cancer trial

The CDK 4/6 inhibitor failed to improve overall survival in a late-stage study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links